广告
加载中

药师帮2024中期业绩:净利润首次转正 超1300万

李佳晅 2024-08-27 10:20
李佳晅 2024/08/27 10:20

邦小白快读

EN
全文速览

药师帮2024中期业绩显示强劲增长和首次盈利,核心数据亮点突出。

1. 收入达88.1亿元,同比增长10.6%;净利润首次转正超1300万元,经调净利润超9100万元增30.3%;经营性现金流4.2亿元正流入增14.6%。

2. 用户规模扩大:药店用户42.6万家,基层医疗机构31万家,月均活跃买家42.5万增20.4%,付费率93%,每付费买家月均下单28单。

3. 效率提升显著:业务拓展团队每人管理约150家药店(同比升超14家),每人带来GMV约820万元增6.4%;库存周转31天,现金循环周期-28.9天高效管理。

4. 服务创新:同城配送“半日达”、“当日达”覆盖17城,58%订单实现半日达(同比提升41%);自有品牌“乐药师”GMV同比增160%,覆盖30万家客户。

品牌相关业务如中药饮片和自有品牌表现亮眼,渠道建设与消费趋势清晰。

1. 品牌营销与渠道:中药饮片业务销售额超9.32亿元增96%,SKU达12.5万个;同城配送服务在17城上线,提升配送效率。

2. 产品研发与趋势:自有品牌“乐药师”已上架超百品种,GMV同比增160%,采购客户突破30万家;大单品藿香正气口服液上市5个月覆盖10万家终端,单月销售额超千万。

3. 用户行为观察:月均买家付费率增至93%,下单频次高,显示品牌粘性强;平台上游商家达8900个,提供丰富合作机会。

平台增长机会丰富,用户需求变化和商业模式创新提供实操指引。

1. 增长市场与需求:药店和医疗机构用户超73万家,活跃买家增20.4%,付费率93%显示高需求;中药饮片销售额增96%,反映消费趋势。

2. 机会提示与应对:独家战略合作品牌及自有品牌业务GMV达2.2亿元增94%,大单品快速覆盖终端;同城配送“半日达”比例提升41%,优化服务竞争力。

3. 风险规避与学习点:库存周转31天和现金循环周期-28.9天确保安全扩张;业务团队人效提升,每人GMV增6.4%,可借鉴管理方法。

生产相关数据和商业机会突出,数字化启示助力业务拓展。

1. 产品需求与设计:平台月均可售SKU达390万个,其中中药饮片SKU超12.5万个,销售额9.32亿元增96%,显示高需求品类。

2. 商业机会:中药饮片业务快速增长,提供生产合作空间;自有品牌“乐药师”品种超百个,覆盖30万家客户,GMV增160%。

3. 数字化启示:库存周转31天、应付账款周转60.6天高效管理,支持快速扩张;平台规模效应放大,上游商家8900个,启示电商整合。

行业趋势与解决方案聚焦效率提升和技术应用。

1. 行业发展趋势:数字化平台用户粘性增强,付费率93%,活跃买家增20.4%;中药饮片销售增96%,反映健康产业增长。

2. 新技术与解决方案:同城配送“半日达”、“当日达”服务在17城上线,58%订单半日达(同比提升41%),优化物流痛点;业务团队人效提升,每人管理药店增14家,GMV增6.4%。

3. 客户痛点应对:库存周转31天和现金循环周期-28.9天提供高效管理方案;平台规模持续放大,启示服务整合机会。

平台运营与需求管理高效,最新做法强化招商和风控。

1. 商业需求与问题解决:用户规模达药店42.6万家和医疗机构31万家,月均活跃买家42.5万增20.4%,付费率93%显示高粘性;应付账款周转60.6天、应收账款周转0.6天优化资金流。

2. 最新做法与招商:同城配送“半日达”、“当日达”覆盖17城,半日达比例58%提升41%,增强服务吸引力;自有品牌“乐药师”GMV增160%,覆盖30万家客户,提供招商亮点。

3. 运营管理与风控:库存周转31天、现金循环周期-28.9天确保高效扩张;业务团队每人GMV820万元增6.4%,提升运营效率;现金流4.2亿元正流入,规避财务风险。

产业动向与商业模式创新突出,政策启示和增长策略清晰。

1. 产业新动向:业绩持续增长,收入88.1亿元增10.6%,净利润首次转正;用户渗透加深,药店和医疗机构用户超73万家,活跃买家增20.4%。

2. 商业模式创新:平台规模效应放大,上游商家8900个,SKU达390万个;自有品牌“乐药师”GMV增160%,大单品快速覆盖终端,显示品牌整合模式。

3. 效率与政策启示:库存周转31天、现金循环周期-28.9天的高效管理;同城配送服务提升物流效率,启示数字化政策支持;业务人效提升,每人管理药店增14家,提供运营优化案例。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Yaoshi Bang's 2024 interim results demonstrate robust growth and its first-ever profitability, with core metrics showing significant strength.

1. Revenue reached RMB 8.81 billion, a 10.6% year-on-year increase; Net profit turned positive for the first time, exceeding RMB 13 million, while adjusted net profit grew 30.3% to over RMB 91 million; Operating cash flow was a positive inflow of RMB 420 million, up 14.6%.

2. User base expanded: Pharmacy users reached 426,000, primary medical institutions totaled 310,000; Monthly active buyers averaged 425,000, a 20.4% increase, with a 93% paying rate; Each paying buyer placed an average of 28 orders per month.

3. Efficiency improved markedly: Each business development team member managed approximately 150 pharmacies (up by over 14 YoY), generating about RMB 8.2 million in GMV per person, a 6.4% increase; Inventory turnover was 31 days, with an efficient cash conversion cycle of -28.9 days.

4. Service innovation: Same-day and half-day delivery services covered 17 cities, with 58% of orders fulfilled within half a day (a 41% YoY improvement); The proprietary brand "Le Yaoshi" saw GMV surge 160% YoY, reaching 300,000 customers.

Brand-related segments, such as traditional Chinese medicine decoction pieces and proprietary brands, delivered strong performance, with clear channel development and consumption trends.

1. Brand marketing & channels: Sales of TCM decoction pieces exceeded RMB 932 million, up 96%, with SKUs reaching 125,000; Same-day delivery services launched in 17 cities, enhancing distribution efficiency.

2. Product R&D & trends: The proprietary brand "Le Yaoshi" now offers over 100 product varieties, with GMV growing 160% YoY and serving over 300,000 purchasing clients; The flagship product Huoxiang Zhengqi Oral Solution reached 100,000 terminals within 5 months, achieving monthly sales exceeding RMB 10 million.

3. User behavior insights: The monthly paying buyer rate increased to 93%, with high order frequency indicating strong brand loyalty; The platform hosts 8,900 upstream merchants, offering abundant partnership opportunities.

The platform offers substantial growth opportunities, with evolving user demand and business model innovations providing practical guidance.

1. Growth markets & demand: Over 730,000 pharmacy and medical institution users, with active buyers up 20.4% and a 93% paying rate indicating strong demand; TCM decoction piece sales surged 96%, reflecting consumption trends.

2. Opportunity alerts & strategies: Exclusive strategic partnership brands and proprietary brand business GMV reached RMB 220 million, up 94%, with flagship products rapidly penetrating terminals; The share of half-day same-day delivery increased 41%, optimizing service competitiveness.

3. Risk mitigation & learnings: Inventory turnover of 31 days and a cash conversion cycle of -28.9 days ensure safe expansion; Business team efficiency improved, with per-person GMV up 6.4%, offering manageable methods to adopt.

Production-related data and commercial opportunities are highlighted, with digital insights aiding business expansion.

1. Product demand & design: The platform offers an average of 3.9 million monthly sellable SKUs, including over 125,000 TCM decoction piece SKUs, with sales of RMB 932 million (up 96%), indicating high-demand categories.

2. Commercial opportunities: Rapid growth in TCM decoction pieces provides production collaboration potential; The proprietary brand "Le Yaoshi" covers over 100 varieties, serving 300,000 clients, with GMV up 160%.

3. Digital insights: Efficient management with 31-day inventory turnover and 60.6-day accounts payable turnover supports rapid scaling; Platform scale effects amplify, with 8,900 upstream merchants illustrating e-commerce integration potential.

Industry trends and solutions focus on efficiency gains and technology application.

1. Industry trends: Digital platform user stickiness strengthened, with a 93% paying rate and active buyers up 20.4%; TCM decoction piece sales grew 96%, reflecting health industry expansion.

2. New tech & solutions: Half-day and same-day delivery services launched in 17 cities, with 58% of orders half-day delivered (up 41% YoY), addressing logistics pain points; Business team efficiency rose, with each member managing 14 more pharmacies and GMV per person up 6.4%.

3. Addressing client pain points: Inventory turnover of 31 days and a cash conversion cycle of -28.9 days offer efficient management models; Continued platform scaling reveals service integration opportunities.

Platform operations and demand management are highly efficient, with latest practices enhancing merchant acquisition and risk control.

1. Business needs & solutions: User base includes 426,000 pharmacies and 310,000 medical institutions; Monthly active buyers averaged 425,000 (up 20.4%), with a 93% paying rate indicating strong loyalty; Accounts payable turnover of 60.6 days and receivables turnover of 0.6 days optimize cash flow.

2. Latest practices & merchant acquisition: Half-day and same-day delivery coverage expanded to 17 cities, with half-day orders reaching 58% (up 41%), boosting service appeal; Proprietary brand "Le Yaoshi" GMV surged 160%, covering 300,000 clients, providing key acquisition highlights.

3. Operations & risk control: Inventory turnover of 31 days and a cash conversion cycle of -28.9 days ensure efficient expansion; Business team GMV per person reached RMB 8.2 million (up 6.4%), enhancing operational efficiency; Positive operating cash flow of RMB 420 million mitigates financial risks.

Industry movements and business model innovations are prominent, with clear policy implications and growth strategies.

1. Industry trends: Sustained performance growth with revenue of RMB 8.81 billion (up 10.6%) and first-time net profit positivity; User penetration deepened, surpassing 730,000 pharmacy and medical institution users, with active buyers up 20.4%.

2. Business model innovation: Platform scale effects amplified, with 8,900 upstream merchants and 3.9 million SKUs; Proprietary brand "Le Yaoshi" GMV grew 160%, and flagship products rapidly covered terminals, demonstrating brand integration models.

3. Efficiency & policy implications: Highly efficient management with 31-day inventory turnover and -28.9-day cash conversion cycle; Same-day delivery services improve logistics efficiency, suggesting digital policy support; Operational efficiency gains, with each team member managing 14 more pharmacies, providing optimization case studies.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】8月26日晚间,院外医药产业数字化服务平台药师帮发布2024半年度报告,公司收入继续保持两位数增长,盈利能力不断提升。报告期内,公司营业收入88.1亿元,同比增长10.6%;净利润超1300万元,由亏损首次转正;经调净利润超9100万元,同比增长30.3%;经营性现金流继续保持正向流入达4.2亿元,同比增长14.6%。

药师帮的平台规模效应持续放大,用户渗透深度及粘性进一步提升。报告期内,药店用户达42.6万家,基层医疗机构用户达31万家,月均活跃买家数量达42.5万,同比增长20.4%;月均买家付费率增至93%,每付费买家月均下单次数约为28单。

目前,公司平台上游商家达8900个,月均可售SKU达390万个。其中,公司大力发展中药饮片饮片业务,平台可供应超过12.5万个SKU,销售额超9.32亿元,同比增长96%。

在保持规模增速的同时,公司也更加重视经营效率的提升,业务拓展团队的人效进一步提升,每名成员平均可管理约150家药店,较去年同期上升超过14家;报告期内每名业务拓展团队成员可带来约人民币820万元的GMV,同比增长6.4%。

自营业务部分,公司应付账款周转天数约60.6天,应收账款周转天数约0.6天,库存周转31天,现金循环周期约—28.9天,实现了高效的库存与现金管理,为安全快速扩大整体业务规模提供了保障。与此同时,药师帮在17个城市上线"半日达"、"当日达"的同城配送服务。报告期内,约58%的同城订单实现半日达,相比去年同期提升超过41%。

在不断提升常规自营业务的服务竞争力的基础上,药师帮在报告期内重点拓展独家战略合作品牌及自有品牌"乐药师"产品业务,这两项细分业务产品GMV达2.2亿元,同比增长94%。其中,药师帮自有品牌"乐药师"已上架品种超百个、累计采购客户数突破30万家,GMV同比增长160%;大单品藿香正气口服液上市5个月覆盖约10万家终端用户,今年6月份单月销售额超过千万。


文章来源:亿邦动力

广告
微信
朋友圈

FAQ回顾

药师帮2024年上半年主要财务业绩如何?

药师帮2024年上半年营业收入88.1亿元,同比增长10.6%;净利润首次转正超1300万元,经调净利润9100万元增长30.3%;经营性现金流4.2亿元,同比增长14.6%。

药师帮平台用户规模和业务数据有哪些增长?

平台药店用户42.6万家,基层医疗机构31万家,月均活跃买家42.5万增长20.4%;月均买家付费率93%,每付费买家月均下单28单;上游商家8900个,月均可售SKU 390万个。

药师帮在业务拓展方面有哪些重点举措?

重点发展中药饮片业务,SKU超12.5万个,销售额9.32亿元增长96%;自有品牌'乐药师'GMV增长160%;在17个城市推出'半日达'服务,58%同城订单实现半日达。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0